Iterum Therapeutics (ITRM) Competitors $0.72 -0.02 (-3.09%) Closing price 08/25/2025 03:58 PM EasternExtended Trading$0.72 +0.00 (+0.42%) As of 08/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. BHST, KYTX, THTX, MCRB, BTMD, IOBT, MOLN, IMRX, GNLX, and HURAShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include BioHarvest Sciences (BHST), Kyverna Therapeutics (KYTX), Theratechnologies (THTX), Seres Therapeutics (MCRB), biote (BTMD), IO Biotech (IOBT), Molecular Partners (MOLN), Immuneering (IMRX), Genelux (GNLX), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Its Competitors BioHarvest Sciences Kyverna Therapeutics Theratechnologies Seres Therapeutics biote IO Biotech Molecular Partners Immuneering Genelux TuHURA Biosciences BioHarvest Sciences (NASDAQ:BHST) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation. Is BHST or ITRM more profitable? Iterum Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -39.95%. Iterum Therapeutics' return on equity of 0.00% beat BioHarvest Sciences' return on equity.Company Net Margins Return on Equity Return on Assets BioHarvest Sciences-39.95% -11,357.84% -39.94% Iterum Therapeutics N/A N/A -65.01% Do insiders & institutionals believe in BHST or ITRM? 9.2% of Iterum Therapeutics shares are owned by institutional investors. 2.4% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer BHST or ITRM? BioHarvest Sciences currently has a consensus price target of $13.67, indicating a potential upside of 64.66%. Iterum Therapeutics has a consensus price target of $9.00, indicating a potential upside of 1,148.27%. Given Iterum Therapeutics' higher possible upside, analysts clearly believe Iterum Therapeutics is more favorable than BioHarvest Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioHarvest Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor BHST or ITRM? In the previous week, Iterum Therapeutics had 3 more articles in the media than BioHarvest Sciences. MarketBeat recorded 3 mentions for Iterum Therapeutics and 0 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score. Company Overall Sentiment BioHarvest Sciences Neutral Iterum Therapeutics Neutral Which has more risk and volatility, BHST or ITRM? BioHarvest Sciences has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.85, suggesting that its share price is 185% more volatile than the S&P 500. Which has stronger earnings and valuation, BHST or ITRM? BioHarvest Sciences has higher revenue and earnings than Iterum Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioHarvest Sciences$25.19M5.41-$12.91M-$0.70-11.86Iterum TherapeuticsN/AN/A-$24.77M-$0.85-0.85 SummaryIterum Therapeutics beats BioHarvest Sciences on 8 of the 13 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.23M$2.54B$5.81B$9.74BDividend YieldN/A1.68%4.40%4.08%P/E Ratio-0.8522.4130.1425.84Price / SalesN/A552.95432.88102.91Price / CashN/A26.0925.7828.79Price / Book-4.815.529.425.99Net Income-$24.77M$31.83M$3.27B$265.29M7 Day Performance-13.22%2.99%3.64%4.07%1 Month Performance-10.16%0.83%3.52%0.93%1 Year Performance-38.38%6.16%29.94%18.21% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics1.7915 of 5 stars$0.72-3.1%$9.00+1,148.3%-40.4%$33.23MN/A-0.8510BHSTBioHarvest SciencesN/A$9.60+3.0%$13.67+42.4%N/A$153.14M$25.19M-13.71N/AGap UpKYTXKyverna Therapeutics2.5533 of 5 stars$3.54+0.9%$15.60+340.7%-52.9%$151.79M$7.03M-0.9696THTXTheratechnologiesN/A$3.24flatN/A+145.3%$148.98M$85.87M-17.05140MCRBSeres Therapeutics2.5317 of 5 stars$17.69+6.0%$73.67+316.4%+10.4%$146.11MN/A-3.85330BTMDbiote2.1732 of 5 stars$3.02+3.4%$6.00+98.7%-45.8%$144.36M$197.19M3.36194IOBTIO Biotech3.3087 of 5 stars$2.09-3.2%$8.67+314.7%+4.3%$142.30MN/A-1.3230MOLNMolecular Partners1.6702 of 5 stars$3.51+1.2%$12.00+241.9%-32.3%$140.10M$5.65M-1.83180News CoverageEarnings ReportGap UpHigh Trading VolumeIMRXImmuneering3.4833 of 5 stars$3.50-6.9%$13.25+278.6%+456.1%$136.56M$320K-1.8560News CoverageGap DownGNLXGenelux1.711 of 5 stars$3.54-0.6%$17.75+401.4%+65.5%$134.47M$10K-4.1210HURATuHURA Biosciences1.4576 of 5 stars$3.09+1.0%$12.67+309.9%N/A$133.66MN/A0.00N/A Related Companies and Tools Related Companies BioHarvest Sciences Alternatives Kyverna Therapeutics Alternatives Theratechnologies Alternatives Seres Therapeutics Alternatives biote Alternatives IO Biotech Alternatives Molecular Partners Alternatives Immuneering Alternatives Genelux Alternatives TuHURA Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access